Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity
Authors:
- 26 June 2007
- journal article
- Published by Wiley in Cancer Science
- Vol. 98 (9) , 1408-1412
Abstract
To determine whether bodyweight (BW) loss, daily urine volume (UV) or furosemide use are associated with cisplatin nephrotoxicity, performance status, serum chemistries before treatment, average daily UV, maximum BW loss and use of furosemide on days 1–5 of chemotherapy were evaluated retrospectively in chemotherapy‐naive patients with thoracic malignancies who had received 80 mg/m2 cisplatin. Associations between these parameters and the worst serum creatinine levels (group 1, grade 0–1; and group 2, grade 2–3) during the first cycle were evaluated. Of the 417 patients (327 men and 90 women; median age, 59 years), 390 were categorized into group 1 and 27 were categorized into group 2. More women and older patients were observed in group 2 than in group 1 (11.1 vs 5.2%, P = 0.044, and 65 vs 59 years, P = 0.041, respectively). The median average daily UV was 3902 mL in group 1 and 3600 mL in group 2 (P = 0.021). A maximum BW loss ≥2.1 kg was noted in 4.4% of patients in group 1 and 18.5% of patients in group 2 (P = 0.006). Furosemide was used in 206 (49.4%) patients. The median total dose of furosemide in groups 1 and 2 were 0 mg and 26 mg, respectively (P = 0.024). A multivariate analysis showed that a maximum BW loss ≥2.1 kg and the total furosemide dose were significantly associated with group category. In conclusion, BW loss and total furosemide dose were associated with cisplatin nephrotoxicity. (Cancer Sci 2007; 98: 1408–1422)Keywords
This publication has 17 references indexed in Scilit:
- Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Carboplatin Equals Cisplatin: But How Do I Prescribe It?Journal of Clinical Oncology, 2003
- Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trialCancer Chemotherapy and Pharmacology, 2003
- Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patientsBritish Journal of Cancer, 2003
- WaterJournal of the American Dietetic Association, 1999
- Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and CarboplatinJournal of Clinical Oncology, 1999
- Cancer Chemotherapy in the ElderlyJapanese Journal of Clinical Oncology, 1998
- Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methodsCancer Chemotherapy and Pharmacology, 1997
- Nephrotoxicity and Hydration Management for Cisplatin, Carboplatin, and OrmaplatinGynecologic Oncology, 1993
- High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresisCancer, 1977